Clinical trials: Toxicity, active
Hematologic Diseases, Chronic Myeloid Leukemia
Muscle Dysfunction in Patients With Hematological Diseases Referred to Stem Cell Transplant
PURPOSE: To investigate the effect of the disease and HSCT on muscle dysfunction and to investigate the prognostic role of muscle dysfunction at critical decision points in patients with hematological diseases referred to…
- Conditions
- Hematologic Diseases, Chronic Myeloid Leukemia, Acute Myeloid Leukemia, Acute Lymphoid Leukemia
- Trial name
- NCT04167683
- Testing
- No intervention
- Where
- Denmark
- Volunteers
- 144 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Radiation Injuries
Oral 5 Strain Probiotic for GI Toxicity Mitigation During Pelvic Radiation
This research is to determine if an oral probiotic, Pendulum Glucose Control (PGC), can be safely given to patients during pelvic radiation therapy (RT).
- Trial name
- NCT07231588
- Testing
- Pendulum Glucose Control (PGC)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Cincinnati
Prostate Cancer, Prostate Adenocarcinoma
Reduction of Gastrointestinal Toxicity in Prostate Cancer by Proton Spot Placement
This purpose of this study is to examine the placement of proton spots during pencil beam scanning proton therapy for low and intermediate risk prostate cancer.
- Conditions
- Prostate Cancer, Prostate Adenocarcinoma, Prostate Carcinoma
- Trial name
- NCT06200259
- Testing
- Spot Delete planning for proton therapy, Traditional proton treatment planning system
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Covenant Health Cancer Center
Cardiotoxicity Induced by Drug Therapy for Breast Cancer
The Use of Shengmai San to Prevent Anthracycline Sequential Trastuzumab Therapy Related Cardiac Toxicity
To evaluate the effectiveness and safety of Shengmai San in preventing anthracycline sequential trastuzumab therapy related cardiac toxicity through a prospective randomized controlled study.
- Trial name
- START (NCT06214195)
- Testing
- Shengmai San (ingredients include ginseng, Ophiopogon japonicus, and Schisandra chinensis)
- Where
- China
- Volunteers
- 276 people
- Sponsor
- Zhejiang Cancer Hospital
Renal Cell Carcinoma
Intensified Monitoring of PhArmacology of Cabozantinib as a Tool for Toxicity Management in Patients With Renal Cell Carcinoma
Adverse events (AEs) with Cabozantinib are frequent (about 40-67% of patients) and often lead to temporary treatment interruptions, dose reductions or permanent discontinuations, potentially reducing dose intensity and sustained…
- Trial name
- IMPACT (NCT07805122)
- Testing
- Intensified Monitoring of Pharmacology
- Where
- Italy
- Volunteers
- 216 people
- Sponsor
- Centro di Riferimento Oncologico - Aviano
Chronic Pelvic Pain Syndrome (CPPS), Radiation-Induced Disorder
Gene and Molecular Pathways of Ozone Treatment Response in Gynecological Tumor Patients With Chronic Pelvic Pain Secondary to Cancer Treatment
Gynecological cancers, including those affecting the ovaries, uterus, and cervix, represent a significant health burden for women.
- Conditions
- Chronic Pelvic Pain Syndrome (CPPS), Radiation-Induced Disorder, Radiotherapy Side Effects, Side Effect of Chemotherapy
- Trial name
- OzoGynEpigen (NCT06816095)
- Where
- Spain
- Volunteers
- 40 people
- Sponsor
- Bernardino Clavo, MD, PhD
Anthracycline Related Cardiotoxicity in Childhood Cancers, Chemotherapeutic Toxicity
Evaluation of Cardiac and Endothelial Function in Children and Adolescents Treated With Anthracycline
In recent decades, the survival rate of children with cancer has increased significantly thanks to personalized treatments and the adoption of international therapeutic protocols.
- Conditions
- Anthracycline Related Cardiotoxicity in Childhood Cancers, Chemotherapeutic Toxicity, Childhood Cancer Survivors
- Trial name
- CARDIO-PED (NCT07253077)
- Testing
- Biomarker detection
- Where
- Italy
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Financial Hardship, Alzheimer's Disease (AD)
Development of Measures to Screen for Financial Hardship in Alzheimer's Disease and Dementia
Alzheimer's Disease and related dementias (AD/ADRD) are common and debilitating conditions. Financial hardship, a multidimensional construct of financial strain, financial stress and asset depletion, is common in AD/ADRD due to…
- Conditions
- Financial Hardship, Alzheimer's Disease (AD), Alzheimer's Disease and Related Dementia (ADRD)
- Trial name
- AD/ADRD (NCT06922188)
- Where
- United States
- Volunteers
- 2,460 people, healthy volunteers welcome
- Sponsor
- Fred Hutchinson Cancer Center
Neuroendocrine (NE) Tumors
Survival Without Persistent Limiting Toxicity: Real Life Prospective Cohort of Advanced Neuroendocrine Tumor
Advanced neuroendocrine tumors (NETs) are rare cancers, characterized by prolonged survival (median>5 years). If five medical options are now approved and 4 others are only recommended, the best sequence is still unknown.
- Trial name
- TOLERATE (NCT07471425)
- Testing
- quality of life questionnaire, treatment side effect follow up
- Where
- 14 sites in France
- Volunteers
- 1,100 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Radiation Necrosis, High Grade Glioma (III or IV)
Bevacizumab Versus Corticosteroids as First-line Treatment in Patients With Symptomatic Cerebral Radiation Necrosis After Radiation for High-grade Glioma or Brain Metastases
Cerebral radiation necrosis (CRN) is a severe complication of high-dose radiation for brain metastases (BM) or glioma, which can potentially cause significant neurologic symptoms leading to serious morbidity and impaired quality…
- Conditions
- Radiation Necrosis, High Grade Glioma (III or IV), Brain Metastasases, Radiation Toxicity
- Trial name
- BRAINS (NCT06888817)
- Testing
- Bevacizumab, Dexamethasone
- Where
- 6 sites in Netherlands
- Volunteers
- 408 people
- Sponsor
- The Netherlands Cancer Institute
Neoplasms
Health Effects of CArdiac FluoRoscopy and MOderN RadIotherapy in PediatriCs - Radiotherapy
The goal of the HARMONIC-RT study is to evaluate late health and social outcomes of contemporary techniques of external beam radiotherapy in paediatric patients, based on the setting-up of a European, long-term registry…
- Trial name
- HARMONIC-RT (NCT04746729)
- Testing
- No intervention
- Where
- 5 sites in Belgium, Denmark and 2 more
- Volunteers
- 2,670 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Breast Cancer, eHealth
Mitigating Toxicity by Electronic Health Portal-mediated Interactive Monitoring of Patient-reported Side Effects
Chemotherapy induces side effects varying in severity, impacting patients' quality of life and necessitating unplanned hospital care. Patient-reported outcomes (PROs) could aid in early detection and management of side effects.
- Conditions
- Breast Cancer, eHealth, Symptom Monitoring, Self Management
- Trial name
- eChemoCoach (NCT06424054)
- Testing
- eChemoCoach
- Volunteers
- 746 people
- Sponsor
- Noordwest Ziekenhuisgroep
Breast Neoplasms, Quality of Life (QOL)
A Study of Treatment-Related Toxicities and Quality of Life After Local Therapy in Chinese Breast Cancer Patients
This study, called PERSEVERE, examines how local treatment for early breast cancer affects people's health and daily lives over time.
- Conditions
- Breast Neoplasms, Quality of Life (QOL), Toxicities, Breast Diseases
- Trial name
- PERSEVERE (NCT07010939)
- Testing
- blood sampling
- Where
- 3 sites in China
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- FangYi
Non Small Cell Lung Cancer Stage III, Immunotherapy
Response and Toxicity Prediction by Microbiome Analysis After (Concurrent) Chemoradiotherapy
The predictive value of the microbiome (throat swabs, stool and of bronchial samples) to identify patients who will relapse during durvalumab treatment after CRT (False negative Rate) at 6 months.
- Trial name
- Prediction (NCT04711330)
- Where
- 6 sites in Belgium, Netherlands
- Volunteers
- 126 people
- Sponsor
- Leiden University Medical Center
HER2-positive Breast Cancer
Tucatinib in Combination With Oral Etoposide andTrastuzumab in Patients With Metastatic HER2+ Breast Cancer
This is an open-label, multicenter, phase II study to evaluate the efficacy, safety, tolerability, pharmacokinetics of the combination of tucatinib-Oral VP16-trastuzumab in patients with HER2-positive metastatic breast cancer…
- Trial name
- TUC-TOC (NCT05955170)
- Testing
- Tucatinib in Combination of Oral VP16 and trastuzumab
- Where
- 13 sites in France
- Volunteers
- 66 people
- Sponsor
- Institut Curie
Tumor, Solid
Phase II Study of Intensity Modulated Radiotherapy in Dose Painting for Sinus Carcinomas After Endoscopic Surgery
The patient is randomized to one of the following groups: Experimental group: Radiotherapy in painting dose on histoscannographic mapping Control group: standard pan-sinus radiotherapy
- Trial name
- SinocaRT (NCT05943119)
- Testing
- Radiotherapy in painting dose on histoscannographic mapping, Standard pan-sinusal Radiotherapy
- Where
- 3 sites in France
- Volunteers
- 52 people
- Sponsor
- Centre Francois Baclesse
Glioma
Investigating Mechanistic Predictors of Interpatient Variability and Temozolomide (TMZ) Induced Haematological Toxicity for Glioma Patients
A medication called temozolomide has been used for many years in the treatment of high-grade gliomas, which are tumours that originate in the brain.
- Trial name
- Improve TMZ (NCT06546631)
- Where
- Ireland
- Volunteers
- 55 people
- Sponsor
- University College Cork
Neuropathy, Cancer
Daily Hand-Held Vibration Therapy
The purpose of this pilot study is to determine the safety and feasibility of a daily 3-minute hand-held vibration therapy intervention to reduce the severity of CIPN in the hands.
- Conditions
- Neuropathy, Cancer, Chemotherapeutic Drug - Induced Nephropathy, Chemotherapeutic Toxicity
- Trial name
- NCT04207437
- Testing
- Vibration therapy
- Where
- 3 sites in United States
- Volunteers
- 16 people
- Sponsor
- Indiana University
Breast Cancer Female, Thyroid Gland
Evaluation of Thyroid Abnormity Incidence and Thyroid Toxicity During Chemotherapy Among Newly Diagnosed Breast Cancer
Breast cancer is one of the most common cancers in China. Even though advances in the field of breast cancer therapeutics, chemotherapy remains the mainstay therapeutic modality.
- Trial name
- NCT03177902
- Testing
- Chemotherapy
- Where
- China
- Volunteers
- 400 people
- Sponsor
- The First Affiliated Hospital of Bengbu Medical University
Heart Failure, Cardiotoxicity
The STOP-MED CTRCD Trial
Cancer therapy-related cardiac dysfunction (CTRCD) is when the heart's ability to pump oxygenated blood to the body is compromised. It is a side effect of cancer therapy which can occur as commonly as in 1 in 5 patients.
- Conditions
- Heart Failure, Cardiotoxicity, Cardiac Toxicity, Antineoplastics Toxicity
- Trial name
- STOP-MED CTRCD (NCT06183437)
- Testing
- Stopping Heart Failure Medication(s)
- Where
- 14 sites in United States, Australia and 4 more
- Volunteers
- 335 people
- Sponsor
- Dinesh Thavendiranathan